{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:30:06Z","timestamp":1786483806722,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,23]],"date-time":"2027-07-23T00:00:00Z","timestamp":1816300800000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5U54GM104942-08"],"award-info":[{"award-number":["5U54GM104942-08"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jns.2026.126106","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:19:26Z","timestamp":1784301566000},"page":"126106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity"],"prefix":"10.1016","volume":"489","author":[{"given":"Huanwen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhairya A.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhara S.","family":"Yaddanapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Latifikhereshky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranjal","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Kakadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colasurdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.126106_bb0005","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2026.126106_bb0010","first-page":"12","article-title":"Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity","author":"Michos","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jns.2026.126106_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2026.126106_bb0020","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/STROKEAHA.121.038151","article-title":"Benefits of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists","volume":"53","author":"Goldenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2026.126106_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2026.126106_bb0030","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.126106_bb0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/17474930241253988","article-title":"Glucagon-like peptide-1 receptor agonists and stroke: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"19","author":"Adamou","year":"2024","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.jns.2026.126106_bb0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","article-title":"The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial","volume":"8","author":"Gerstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jns.2026.126106_bb0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00415-025-13470-w","article-title":"Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis","volume":"272","author":"Rai","year":"2025","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126106_bb0050","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/STROKEAHA.126.055692","article-title":"GLP-1 receptor agonist use is associated with lower risk of intracranial aneurysm rupture and rupture severity","volume":"57","author":"Chen","year":"2026","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2026.126106_bb0055","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.70022","article-title":"Seizure recurrence after <scp>GLP<\/scp> -1 receptor agonist initiation in adults with epilepsy","volume":"67","author":"AbuAlrob","year":"2026","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.jns.2026.126106_bb0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/15357597261440716","article-title":"The effect of GLP-1 receptor agonists on epilepsy: no appetite for seizures","volume":"26","author":"Karakis","year":"2026","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.jns.2026.126106_bb0065","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jns.2026.126106_bb0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12933-021-01401-8","article-title":"Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression","volume":"20","author":"Maiorino","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jns.2026.126106_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcjd.2019.09.003","article-title":"Mechanisms by which glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 diabetes mellitus","volume":"44","author":"Sharma","year":"2020","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.jns.2026.126106_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0271678X20952011","article-title":"Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review","volume":"41","author":"Maskery","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:53:17Z","timestamp":1786481597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26003886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"alternative-id":["S0022510X26003886"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126106","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126106"}}